| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font
First page > Show document

Show document Help

Title:Pretirano visoke cene v farmacevtskem sektorju kot oblika zlorabe prevladujočega položaja : magistrsko delo
Authors:ID Dugar, Tamara (Author)
ID Repas, Martina (Mentor) More about this mentor... New window
Files:.pdf MAG_Dugar_Tamara_2019.pdf (1,06 MB)
MD5: A61C445FE06DE9B8F8D630ED54A4FB1A
PID: 20.500.12556/dkum/27767a7a-da5d-45e2-8a66-79a16c47e7f2
 
Language:Slovenian
Work type:Master's thesis/paper
Typology:2.09 - Master's Thesis
Organization:PF - Faculty of Law
Abstract:Magistrsko delo obravnava vprašanje zlorabe prevladujočega položaja v farmacevtskem sektorju, in sicer z zaračunavanjem pretirano visokih cen za zdravila. Avtorica najprej predstavi člen 102 Pogodbe o delovanju EU, ki prevladujočim podjetjem prepoveduje zlorabiti svoj položaj, nato pa značilnosti te oblike omejevalnega ravnanja, njeno presojanje in posebnosti samega farmacevtskega sektorja, ki vplivajo na visoke cene zdravil. Temu sledi predstavitev pojma pretirano visokih cen, kot oblike zlorabe prevladujočega položaja, opisane pa so tudi različne metode presojanja pretirano visokih cen. Nadaljnje so analizirani (sicer redki) primeri, v katerih so konkurenčni organi odločili, da so farmacevtska podjetja zaračunavala pretirano visoke cene za zdravila in tako zlorabila svoj prevladujoč položaj, nato pa so predstavljeni še ukrepi, ki lahko poleg konkurenčnopravnega nadzora vplivajo na nižje cene zdravil. Avtorica ugotavlja, da je moč zaznati naraščajoče zanimanje konkurenčnih organov za preganjanje izkoriščevalskih oblik zlorab farmacevtskih podjetij, kamor spada zaračunavanje pretirano visokih cen za zdravila. Pri presojanju, ali so cene pretirano visoke, so konkurenčni organi v obravnavanih odločbah sledili dvostopenjskemu testu, ki ga je Sodišče EU predstavilo v zadevi United Brands, zato se je ta metoda izkazala kot primerna za presojanje neupravičeno visokih cen farmacevtskih proizvodov. Za samo preprečevanje zaračunavanja previsokih cen za zdravila pa je smiselno konkurenčnopravni nadzor kombinirati še z drugimi ukrepi, kot so povečanje izravnalne kupne moči, ustrezna regulacija cen zdravil in povečanje transparentnosti glede stroškov farmacevtskih podjetij.
Keywords:konkurenčno pravo EU, zloraba prevladujočega položaja, pretirano visoke cene, farmacevtski sektor, farmacevtski proizvodi, zdravstvo
Place of publishing:[Maribor
Place of performance:[Maribor
Publisher:T. Dugar]
Year of publishing:2019
Number of pages:V, 79 str.
PID:20.500.12556/DKUM-75489 New window
UDC:339.137(043.3)
COBISS.SI-ID:5828139 New window
NUK URN:URN:SI:UM:DK:5YIRLU3S
Publication date in DKUM:20.12.2019
Views:2082
Downloads:279
Metadata:XML DC-XML DC-RDF
Categories:PF
:
DUGAR, Tamara, 2019, Pretirano visoke cene v farmacevtskem sektorju kot oblika zlorabe prevladujočega položaja : magistrsko delo [online]. Master’s thesis. Maribor : T. Dugar. [Accessed 16 March 2025]. Retrieved from: https://dk.um.si/IzpisGradiva.php?lang=eng&id=75489
Copy citation
  
Average score:
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
(0 votes)
Your score:Voting is allowed only for logged in users.
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:26.11.2019

Secondary language

Language:English
Title:Excessive prices in pharmaceutical sector as a type of abuse of a dominant position
Abstract:Master's thesis addresses the issue of abuse of a dominant position in the pharmaceutical sector by charging excessively high prices for medicines. The author starts by presenting the Article 102 of the Treaty on the Functioning of the EU, which prohibits dominant undertakings from abusing their position, and describes the characteristics of the abuse of dominant position, its assessment and the particularities of the pharmaceutical sector, which affect the high prices of medicines. The author further presents the concept of excessive pricing as a form of abuse of a dominant position and describes various methods for assessing the excessiveness of the prices. This is followed by a close analysis of (rare) cases where the competition authorities decided that pharmaceutical companies were guilty of charging excessively high prices for medicines and thus abused their dominant position. Lastly, the author presents measures that may, in addition to competition enforcement, help in lowering the prices of medicines. The author establishes that there is a growing interest of competition authorities in investigating exploitative forms of abuse by pharmaceutical companies, which includes excessive pricing of medicines. In assessing whether the prices were excessively high, the competition authorities followed the two-stage test presented by the Court of Justice of the EU in the case United Brands. This method therefore proved to be appropriate for the assessment of excessive prices of pharmaceutical products. In order to prevent unduly high prices of medicines, however, it is appropriate to combine competition law enforcement with other measures, such as increasing countervailing buyer power, appropriate price regulation of medicines and increasing transparency regarding the costs of pharmaceutical companies.
Keywords:EU competition law, abuse of dominant position, excessive prices, pharmaceutical sector, pharmaceuticals, healthcare


Comments

Leave comment

You must log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica